These findings support the significant anti-leukemic effect of anti-CCRL2 ADC in TP53-mutated MDS/AML and particularly erythroleukemic samples is likely associated with the prominent overexpression of the target in these subsets and not with their cell intrinsic sensitivity to the released toxin. This evidence concerns the gene CCRL2 and myelodysplastic syndrome.